2012-09-27 18:22:28 - Recently published research from Datamonitor, "Aveo Pharmaceuticals, Inc.: PharmaVitae Report", is now available at Fast Market Research

This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Scope
* Patient-based forecasts for Aveo's lead candidate, tivozanib, supported by key opinion leader research
* Assessment of Aveo's corporate strategy, operating performance, and earlier-stage pipeline

Highlights

Aveo's lead candidate is tivozanib, a small molecule oral angiogenesis inhibitor. Its primary indication (for which it plans to seek US approval) is in metastatic renal cell carcinoma, but Aveo is also developing the drug for colorectal cancer and breast cancer.

Aveo plans

to submit a New Drug Application for tivozanib in the third quarter of 2012, while commercialization partner Astellas will submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2012.


Full Report Details at
- www.fastmr.com/prod/464846_aveo_pharmaceuticals_inc_pharmavitae_ ..


Reasons to Get this Report
* Evaluate the potential of Aveo's Phase III oncology product, tovozanib
* Assess the potential of the company's earlier-stage pipeline of novel antibodies

Report Table of Contents:

ABOUT THIS REPORT

* PharmaVitae Explorer database
* Chapter structure

* Sales and product analysis
* Financial analysis

* Data sourcing

* Analyst consensus

EXECUTIVE SUMMARY

* Company introduction

* Recent developments
* Corporate relationships

* Strategic overview
* SWOT analysis

* Strengths
* Weaknesses
* Opportunities
* Threats

SALES AND PRODUCT ANALYSIS

* Sales overview
* Product analysis

* Product sales

* Tivozanib

* Targeted therapies provide much-needed therapeutic options in RCC
* Sutent (sunitinib; Pfizer)
* Nexavar (sorafenib; Bayer/Onyx)
* Votrient (pazopanib; GlaxoSmithKline)
* Inlyta (axitinib; Pfizer)
* Combinations of targeted therapies may be increasingly used
* Clinical trials
* Factors affecting approval and use
* Key forecasting assumptions

* Other products

* AV-203

FINANCIAL ANALYSIS

* Financial performance overview

* Operating costs and profit analysis, 2006-11
* Operating costs and profit analysis, 2012-17

APPENDIX

* References
* Exchange rates

TABLES

* Table: Key Aveo corporate relationships
* Table: Aveo key product sales, by region ($m), 2012-17
* Table: Aveo's Phase III clinical trial program in RCC
* Table: Tivozanib US sales forecast model
* Table: Tivozanib EU sales forecast model
* Table: Aveo operating revenue/cost analysis ($m), 2006-11
* Table: Aveo operating revenue/cost analysis ($m), 2012-17
* Table: Exchange rates, 2011

FIGURES

* Figure: PharmaVitae Explorer
* Figure: Aveo prescription pharmaceutical performance, sales ($m) and growth rate 2012-17
* Figure: Aveo key product sales ($m), 2012-17
* Figure: Aveo operating/cost performance ($m), 2004-16

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.